Market Place
Sourcing Support
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With PI
16 Oct 2023 //
GLOBENEWSWIRE
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
19 Sep 2023 //
GLOBENEWSWIRE
ContraFect Announces Submission of IND Application to the FDA for CF-370
18 Sep 2023 //
GLOBENEWSWIRE
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
28 Aug 2023 //
GLOBENEWSWIRE
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 M
27 Jun 2023 //
GLOBENEWSWIRE
ContraFect Data Presentations at ASM Microbe 2023 the Power of the Company
20 Jun 2023 //
GLOBENEWSWIRE
ContraFect Reports 1Q 2023 FYR Results and Provides Business Update
15 May 2023 //
GLOBENEWSWIRE
ContraFect Announces Presentations of New Data at the 33rd Annual ECCMID Meeting
06 Apr 2023 //
GLOBENEWSWIRE
ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase
03 Apr 2023 //
GLOBENEWSWIRE
ContraFect Reports Fourth Quarter 2022 and Full Year 2022 FYR
31 Mar 2023 //
GLOBENEWSWIRE
ContraFect Announces Pricing of $10.0 Million Registered Direct Offering
28 Feb 2023 //
GLOBENEWSWIRE
ContraFect calls for antibiotic study after `uninterpretable` PIII result
20 Dec 2022 //
ENDPTS
Uninterpretable` phase 3 results stymie ContraFect
20 Dec 2022 //
FIERCEBIOTECH
ContraFect Provides Update from Futility Analysis of the PIII Study of Exebacase
19 Dec 2022 //
GLOBENEWSWIRE
ContraFect Announces Pricing of $7.0 Million Registered Direct Offering
13 Dec 2022 //
GLOBENEWSWIRE
ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase
28 Nov 2022 //
GLOBENEWSWIRE
ContraFect Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
ContraFect Announces Presentation of New Clinical Data From a Study Using
12 Sep 2022 //
GLOBENEWSWIRE
ContraFect Announces Multiple Publications Highlighting the Potential Utility
12 Sep 2022 //
GLOBENEWSWIRE
ContraFect Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
ContraFect Announces Publication on Exebacase and CF-296
15 Aug 2022 //
GLOBENEWSWIRE
ContraFect axes staff in wake of PhIII fail; Horizon to fund aB development
15 Aug 2022 //
ENDPTS
ContraFect halts phase 3 after antimicrobial fails futility test
15 Jul 2022 //
FIERCEBIOTECH
ContraFect Announces Independent DSMB Recommends Exebacase PIII DISRUPT Study
13 Jul 2022 //
GLOBENEWSWIRE
ContraFect to Present Data Demonstrating the Potential of DLAs to Combat MRSA
06 Jun 2022 //
GLOBENEWSWIRE
ContraFect Reports First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
ContraFect Announces Multiple Presentations of New Data on DLAs
18 Apr 2022 //
GLOBENEWSWIRE
ContraFect Reports Q4 2021 and Full Year 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
ContraFect to Present at the Maxim Group 2022 Virtual Growth Conference
21 Mar 2022 //
GLOBENEWSWIRE
ContraFect to Present at the SVB Leerink 11th Annual Conference
10 Feb 2022 //
GLOBENEWSWIRE
ContraFect Announces Award from Cystic Fibrosis Foundation to Evaluate Exebacase
06 Jan 2022 //
GLOBENEWSWIRE
ContraFect’s New Data Presented at NACFC Demonstrate of Direct Lytic Agents
09 Nov 2021 //
GLOBENEWSWIRE
ContraFect to Present Data on the Potential of DLAs toPulmonary Infections
26 Oct 2021 //
GLOBENEWSWIRE
ContraFect’s New Phase 2 Exebacase Data Presented at IDWeekTM Demonstrates
04 Oct 2021 //
GLOBENEWSWIRE
ContraFect’s New Phase 2 Exebacase Data Presented at IDWeekTM Demonstrates
04 Oct 2021 //
GLOBENEWSWIRE
ContraFect Corporation to Present at the 2021 Cantor Global Conference
22 Sep 2021 //
GLOBENEWSWIRE
ContraFect Reports Second Quarter 2021 Financial Results
13 Aug 2021 //
GLOBENEWS WIRE
ContraFect Appoints Gary Woodnutt as Senior Vice President
17 Jun 2021 //
GLOBENEWSWIRE
ContraFect Invited to Present New Research Data at World Microbe Forum
17 Jun 2021 //
GLOBENEWSWIRE
ContraFect Announces Multiple Publications Exebacase, First Manuscript
26 May 2021 //
GLOBENEWSWIRE
ContraFect Corporation Prices Public Offering of Common Stock
18 Mar 2021 //
GLOBENEWSWIRE
ContraFect Announces BARDA Contract Award for Up to $86.8 M
11 Mar 2021 //
GLOBENEWSWIRE
ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA
26 Oct 2020 //
GLOBENEWSWIRE
ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation
25 Aug 2020 //
GLOBENEWSWIRE
ContraFect Announces up to $18.9 M in Funding from CARB-X to Support CF-370
20 Jul 2020 //
GLOBENEWSWIRE
Contrafect Announces Publication of Exebacase Ph2 Study Results
17 Jun 2020 //
GLOBENEWSWIRE
ContraFect Corporation Announces Private Placement of Common Stock
26 May 2020 //
GLOBENEWSWIRE
ContraFect Corporation Prices Approximately $52.5 Million Public Offering
22 May 2020 //
GLOBENEWSWIRE
ContraFect Corporation Announces Proposed Public Offering of Common Stock
21 May 2020 //
GLOBENEWSWIRE
ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation
24 Feb 2020 //
YAHOO
